Grants and Contributions:
Title:
Finalizing the Development of a Novel Drug-Device Product for the Treatment and Control of Bleeding Caused by Traumatic Injury
Agreement Number:
1043943
Agreement Value:
$188,500.00
Agreement Date:
Jun 1, 2026 - May 31, 2027
Description:
MACH32 Inc. is developing a novel drug-device combination comprising an autoinjector for the intramuscular (IM) administration of a proprietary formulation of concentrated Tranexamic acid (TXA) drug for treatment of trauma-related bleeding. This proposed project supports the development and commercialization of Firm’s TXA products.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Edmonton, Alberta, CA T6X 0J6
Reference Number:
172-2026-2027-Q1-1043943
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
701428310
Recipient Type:
For-profit organization
Recipient's Legal Name:
MACH32 INC.
Federal Riding Name:
Edmonton--Wetaskiwin
Federal Riding Number:
48021
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
334512